E-cadherin-catenin cell-cell adhesion complex and human cancer

British Journal of Surgery

Volumn 87, Issue 8, 2000, Pages 992-1005

  Wijnhoven, B P L ^a   Dinjens, W N M ^a   Pignatelli, M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CATENIN; UVOMORULIN;

ARTICLE; CANCER; CANCER GROWTH; CELL ADHESION; CELL TRANSFORMATION; CLINICAL PRACTICE; EPITHELIUM CELL; HUMAN; MEDICAL LITERATURE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROTEIN INTERACTION;

ANIMALS; BETA CATENIN; CADHERINS; CELL ADHESION; CYTOSKELETAL PROTEINS; DOGS; GENES, APC; HUMANS; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS; TRANS-ACTIVATORS; WNT PROTEINS; ZEBRAFISH PROTEINS;

EID: 0033930954     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2000.01513.x     Document Type: Article

References (165)

1. St Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 (KIP1). J Cell Biol 1998; 142: 557-71.
2. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51(Suppl 18): 5054-9s.
3. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
4. Menger MD, Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996; 83: 588-601.
5. Jankowski JA, Bedford FK, Kim YS. Changes in gene structure and regulation of E-cadherin during epithelial development, differentiation, and disease. Prog Nucleic Acid Res Mol Biol 1997; 57: 187-215.
6. Shiozaki H, Oka H, Inoue M, Tamura S, Monden M. E-cadherin mediated adhesion system in cancer cells. Cancer 1996; 77(Suppl 8): 1605-13.
7. Riethmacher D, Brinkmann V, Birchmeier C. A targeted mutation in the mouse E-cadherin gene results in defective preimplantation development. Proc Natl Acad Sci U S A 1995; 92: 855-9.
8. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G et al. Structural basis of cell-cell adhesion by cadherins. Nature 1995; 374: 327-37.
9. Tucker EL, Pignatelli M. Catenins and their associated proteins in colorectal cancer. Histol Histopathol 2000; 15: 251-60.
10. Nagafuchi A, Takeichi M. Cell binding function of E-cadherin is regulated by the cytoplasmic domain. EMBO J 1988; 7: 3679-84.
11. Herrenknecht K, Ozawa M, Eckerskorn C, Lottspeich F, Lenter M, Kemler R. The uvomorulin-anchorage protein alpha catenin is a vinculin homologue. Proc Natl Acad Sci U S A 1991; 88: 9156-60.
12. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science 1991; 254: 1359-61.
13. Knudsen KA, Wheelock MJ. Plakoglobin, or an 83-kD homologue distinct from beta-catenin, interacts with E-cadherin and N-cadherin. J Cell Biol 1992; 118: 671-9.
14. Reynolds AB, Daniel J, McCrea PD, Wheelock MJ, Wu J, Zhang Z. Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol 1994; 14: 8333-42.
15. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N et al. Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes. J Cell Biol 1995; 128: 949-57.
16. Aono S, Nakagawa S, Reynolds AB, Takeichi M. p120(ctn) acts as an inhibitory regulator of cadherin function in colon carcinoma cells. J Cell Biol 1999; 145: 551-62.
17. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997; 183: 404-11.
18. Valizadeh A, Karayiannakis AJ, el-Hariry I, Kmiot W, Pignatelli M. Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps. Am J Pathol 1997; 150: 1977-84.
19. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998; 152: 135-44.
20. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85.
21. Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991; 66: 107-19.
22. Watabe M, Nagafuchi A, Tsukita S, Takeichi M. Induction of polarized cell-cell association and retardation of growth by activation of the E-cadherin-catenin adhesion system in a dispersed carcinoma line. J Cell Biol 1994; 127: 247-56.
23. Behrens J, Mareel MM, Van Roy FM, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435-47.
24. Pignatelli M, Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br J Cancer 1992; 66: 629-34.
25. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-3.
26. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174: 243-8.
27. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998; 185: 262-6.
28. Byers SW, Sommers CL, Hoxter B, Mercurio AM, Tozeren A. Role of E-cadherin in the response of tumor cell aggregates to lymphatic, venous and arterial flow: measurement of cell-cell adhesion strength. J Cell Sci 1995; 108: 2053-64.
29. Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996; 56: 4063-70.
30. Akimoto T, Kawabe S, Grothey A, Milas L. Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clin Exp Metastasis 1999; 17: 171-6.
31. Levenberg S, Yarden A, Kam Z, Geiger B. p27 is involved in N-cadherin-mediated contact inhibition of cell growth and S-phase entry. Oncogene 1999; 18: 869-76.
32. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270: 1203-7.
33. Hermiston ML, Wong MH, Gordon JI. Forced expression of E-cadherin in the mouse intestinal epithelium slows cell migration and provides evidence for nonautonomous regulation of cell fate in a self-renewing system. Genes Dev 1996; 10: 985-96.
34. Jankowski JA, Bruton R, Shepherd N, Sanders DS. Cadherin and catenin biology represent a global mechanism for epithelial cancer progression. Mol Pathol 1997; 50: 289-90.
35. Pennisi E. How a growth control path takes a wrong turn to cancer. Science 1998; 281: 1438-9, 1441. (Published erratum appears in Science 1998; 281: 1809.)
36. Barker N, Morin PJ, Clevers H. The Yin-Ying of TCF/beta-catenin signaling. Adv Cancer Res 2000; 77: 1-24.
37. Papkoff J, Rubinfeld B, Schryver B, Polakis P. Wnt-1 regulates free pools of catenins and stabilizes APC-catenin complexes. Mol Cell Biol 1996; 16: 2128-34.
38. Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S et al. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of beta-catenin. J Biol Chem 1998; 273: 10 823-6.
39. Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 1998; 280: 596-9.
40. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3 beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-84.
41. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3beta regulates its stability. J Biol Chem 1999; 274: 10 681-4.
42. Li L, Yuan H, Weaver CD, Mao J, Farr GH III, Sussman DJ et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999; 18: 4233-40.
43. Willert K, Shibamoto S, Nusse R. Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex. Genes Dev 1999; 13: 1768-73.
44. Kikuchi A. Roles of Axin in the Wnt signalling pathway. Cell Signal 1999; 11: 777-88.
45. Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996; 382: 638-42.
46. Clevers H, van de Wetering M. TCF/LEF factor earn their wings. Trends Genet 1997; 13: 485-9.
47. Aoki M, Hecht A, Kruse U, Kemler R, Vogt PK. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA 1999; 96: 139-44.
48. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.
49. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P et al. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999; 18: 2883-91.
50. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M et al. Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999; 96: 1603-8.
51. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 422-6.
52. Hecht A, Litterst CM, Huber O, Kemler R. Functional characterization of multiple transactivating elements in beta-catenin, some of which interact with the TATA-binding protein in vitro. J Biol Chem 1999; 274: 18 017-25.
53. Sanson B, White P, Vincent JP. Uncoupling cadherin-based adhesion from wingless signalling in Drosophila. Nature 1996; 383: 627-30.
54. Fagotto F, Funayama N, Gluck U, Gumbiner BM. Binding to cadherins antagonizes the signaling activity of beta-catenin during axis formation in Xenopus. J Cell Biol 1996; 132: 1105-14.
55. Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A et al. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 1999; 10: 369-76.
56. Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R. Nuclear localization of beta-catenin by interaction with transcription factor LEF-1. Mech Dev 1996; 59: 3-10.
57. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
58. Polakis P. The adenomatous polyposis coli (APC) tumor suppressor. Biochim Biophys Acta 1997; 1332: F127-47.
59. Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S. Alteration of beta-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Res 1996; 56: 2213-17.
60. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 1130-4.
61. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. Beta-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res 1999; 59: 1442-4.
62. Miyoshi Y, Iwao K, Nagasawa Y, Aihara T, Sasaki Y, Imaoka S et al. Activation of the beta-catenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res 1998; 58: 2524-7.
63. Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis. Oncol Res 1998; 10: 591-4.
64. Chan EF, Gat U, McNiff JM, Fuchs E. A common human skin tumour is caused by activating mutations in beta-catenin. Nat Genet 1999; 21: 410-13.
65. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res 1999; 59: 1811-15.
66. Gonzalez MV, Pello MF, Ablanedo P, Suarez C, Alvarez V, Coto E. Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck. J Clin Pathol 1998; 51: 520-4.
67. Sanders DS, Bruton R, Darnton SJ, Casson AG, Hanson I, Williams HK et al. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. Int J Cancer 1998; 79: 573-9. (Published erratum appears in Int J Cancer 1999; 84: 336.)
68. Voeller HJ, Truica CI, Gelmann EP. Beta-catenin mutations in human prostate cancer. Cancer Res 1998; 58: 2520-3.
69. Rimm DL, Caca K, Hu G, Harrison FB, Fearon ER. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am J Pathol 1999; 154: 325-9.
70. Hugh TJ, Dillon SA, Taylor BA, Pignatelli M, Poston GJ, Kinsella AR. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999; 80: 1046-51.
71. Birchmeier W, Hulsken J, Behrens J. Adherens junction proteins in tumour progression. Cancer Surv 1995; 24: 129-40.
72. Tsuda H, Zhang WD, Shimosato Y, Yokota J, Terada M, Sugimura T et al. Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 6791-4.
73. Wijnhoven BP, de Both NJ, van Dekken H, Tilanus HW, Dinjens WN. E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus. Br J Cancer 1999; 80: 1652-7.
74. Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998; 12: 226-37.
75. Berx G, Cleton-Jansen AM, de Strumane K, Leeuw WJ, Nollet F, van Roy F et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13: 1919-25.
76. Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N et al. E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79: 459-65.
77. Soares P, Berx G, van Roy F, Sobrinho-Simoes M. E-cadherin gene alterations are rare events in thyroid tumors. Int J Cancer 1997; 70: 32-8.
78. Schuhmacher C, Becker I, Oswald S, Atkinson MJ, Nekarda H, Becker KF et al. Loss of immunohistochemical E-cadherin expression in colon cancer is not due to structural gene alterations. Virchows Arch 1999; 434: 489-95.
79. Muta H, Noguchi M, Kanai Y, Ochiai A, Nawata H, Hirohashi S. E-cadherin gene mutations in signet ring cell carcinoma of the stomach. Jpn J Cancer Res 1996; 87: 843-8.
80. Vos CB, Cleton-Jansen AM, de Berx G, Leeuw WJ, ter Haar NT, van Roy F et al. E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 1997; 76: 1131-3.
81. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-5.
82. Richards FM, McKee SA, Rajpar MH, Cole TR, Evans DG, Jankowski JA et al. Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 1999; 8: 607-10.
83. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 1999; 155: 337-42.
84. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 1993; 53: 3585-90.
85. Vermeulen SJ, Nollet F, Teugels E, Vennekens KM, Malfait F, Philippe J et al. The alphaE-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells. Oncogene 1999; 18: 905-15.
86. Breen E, Clarke A, Steele G Jr, Mercurio AM. Poorly differentiated colon carcinoma cell lines deficient in alpha-catenin expression express high levels of surface E-cadherin but lack Ca(2+)-dependent cell-cell adhesion. Cell Adhes Commun 1993; 1: 239-50.
87. Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K et al. A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines. Cancer Res 1994; 54: 6282-7.
88. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe N, Niitsu Y. Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the beta-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 1995; 15: 1175-81.
89. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-9.
90. Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, Birchmeier W. Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 1995; 11: 475-84.
91. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M et al. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas. Int J Cancer 1997; 71: 355-9.
92. D'souza B, Taylor-Papadimitriou J. Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene. Proc Natl Acad Sci USA 1994; 91: 7202-6.
93. Palacios J, Benito N, Pizarro A, Limeres MA, Suarez A, Cano A et al. Relationship between ERBB2 and E-cadherin expression in human breast cancer. Virchows Arch 1995; 427: 259-63.
94. Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998; 27: 974-82.
95. Wilding J, Vousden KH, Soutter WP, McCrea PD, Del Buono R, Pignatelli M. E-cadherin transfection down-regulates the epidermal growth factor receptor and reverses the invasive phenotype of human papilloma virus-transfected keratinocytes. Cancer Res 1996; 56: 5285-92.
96. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen-Dale AL. Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 1997; 431: 317-21.
97. Terres AM, Pajares JM, O'Toole D, Ahern S, Kelleher D. H pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J Clin Pathol 1998; 51: 410-12.
98. El-Hariry I, Jordinson M, Lemoine N, Pignatelli M. Characterization of the E-cadherin-catenin complexes in pancreatic carcinoma cell lines. J Pathol 1999; 188: 155-62.
99. Hiscox S, Jiang WG. Expression of E-cadherin, alpha, beta and gamma-catenin in human colorectal cancer. Anticancer Res 1997; 17: 1349-54.
100. Nawrocki B, Polette M, Van Hengel J, Tournier JM, Van Roy F, Birembault P. Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol 1998; 153: 1521-30.
101. Serini G, Trusolino L, Saggiorato E, Cremona O, De Rossi M, Angeli A et al. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 1996; 88: 442-9.
102. Jawhari AU, Noda M, Pignatelli M, Farthing M. Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120ctn in gastric carcinoma. J Pathol 1999; 189: 180-5.
103. Bringuier PP, Giroldi LA, Umbas R, Shimazui T, Schalken JA. Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. Int J Cancer 1999; 83: 591-5.
104. Jawhari AU, Noda M, Farthing MJ, Pignatelli M. Abnormal expression and function of the E-cadherin-catenin complex in gastric carcinoma cell lines. Br J Cancer 1999; 80: 322-30.
105. Skoudy A, Gomez S, Fabre M, Garcia de Herreros A. p120-catenin expression in human colorectal cancer. Int J Cancer 1996; 68: 14-20.
106. Barth AI, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 1997; 9: 683-90.
107. Liu D, el-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997; 77: 557-63.
108. Soler C, Rousselle P, Damour O. Cadherin mediated cell-cell adhesion is regulated by tyrosine phosphatases in human keratinocytes. Cell Adhes Commun 1998; 5: 13-25.
109. Hiscox S, Jiang WG. Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun 1999; 261: 406-11.
110. Muller T, Choidas A, Reichmann E, Ullrich A. Phosphorylation and free pool of beta-catenin are regulated by tyrosine kinases and tyrosine phosphatases during epithelial cell migration. J Biol Chem 1999; 274: 10 173-83.
111. Shiozaki H, Kadowaki T, Doki Y, Inoue M, Tamura S, Oka H et al. Effect of epidermal growth factor on cadherin-mediated adhesion in a human oesophageal cancer cell line. Br J Cancer 1995; 71: 250-8.
112. Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Oku N, Miyazawa K et al. Tyrosine phosphorylation of beta-catenin and plakoglobin enhanced by hepatocyte growth factor and epidermal growth factor in human carcinoma cells. Cell Adhes Commun 1994; 1: 295-305.
113. Tsukatani Y, Suzuki K, Takahashi K. Loss of density-dependent growth inhibition and dissociation of alpha-catenin from E-cadherin. J Cell Physiol 1997; 173: 54-63.
114. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S, Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol 1992; 118: 703-14.
115. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM et al. Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993; 120: 757-66.
116. Nishimura M, Machida K, Imaizumi M, Abe T, Umeda T, Takeshima E et al. Tyrosine phosphorylation of 100-130 kDa proteins in lung cancer correlates with poor prognosis. Br J Cancer 1996; 74: 780-7.
117. Takayama T, Shiozaki H, Doki Y, Oka H, Inoue M, Yamamoto M et al. Aberrant expression and phosphorylation of beta-catenin in human colorectal cancer. Br J Cancer 1998; 77: 605-13.
118. Otto T, Bex A, Schmidt U, Raz A, Rubben H. Improved prognosis assessment for patients with bladder carcinoma. Am J Pathol 1997; 150: 1919-23.
119. Shun CT, Wu MS, Lin JT, Wang HP, Houng RL, Lee WJ et al. An immunohistochemical study of E-cadherin expression with correlations to clinicopathological features in gastric cancer. Hepatogastroenterology 1998; 45: 944-9.
120. Karayiannakis AJ, Syrigos KN, Chatzigianni E, Papanikolaou S, Alexiou D, Kalahanis N et al. Aberrant E-cadherin expression associated with loss of differentiation and advanced stage in human pancreatic cancer. Anticancer Res 1998; 18: 4177-80.
121. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Kosma VM. Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 1999; 80: 477-82.
122. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999; 53: 707-13.
123. Richmond PJ, Karayiannakis AJ, Nagafuchi A, Kaisary AV, Pignatelli M. Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 1997; 57: 3189-93.
124. Blok P, Craanen ME, Dekker W, Tytgat GN. Loss of E-cadherin expression in early gastric cancer. Histopathology 1999; 34: 410-15.
125. Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akaza H, Koiso K et al. Prognostic value of cadherin-associated molecules (alpha-, beta- and gamma-catenins and p120cas) in bladder tumors. Cancer Res 1996; 56: 4154-8.
126. Tamura S, Shiozaki H, Miyata M, Kadowaki T, Inoue M, Matsui S et al. Decreased E-cadherin expression is associated with haematogenous recurrence and poor prognosis in patients with squamous cell carcinoma of the oesophagus. Br J Surg 1996; 83: 1608-14.
127. Maguire TM, Shering SG, McDermott EW, O'Higgins N, Fennelly JJ, Crown J et al. Assay of E-cadherin by ELISA in human breast cancers. Eur J Cancer 1997; 33: 404-8.
128. von Wasielewski R, Rhein A, Werner M, Scheumann GF, Dralle H, Potter E et al. Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 1997; 57: 2501-7.
129. Fischer C, Georg C, Kraus S, Terpe HJ, Luedecke G, Weidner W. CD44s, E-cadherin and PCNA as markers for progression in renal cell carcinoma. Anticancer Res 1999; 19: 1513-17.
130. Gold JS, Reynolds AB, Rimm DL. Loss of p120ctn in human colorectal cancer predicts metastasis and poor survival. Cancer Lett 1998; 132: 193-201.
131. Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne FM et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 1997; 74: 523-8.
132. Shino Y, Watanabe A, Yamada Y, Tanase M, Yamada T, Matsuda M et al. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995; 76: 2193-201.
133. Gabbert HE, Mueller W, Schneiders A, Meier S, Moll R, Birchmeier W et al. Prognostic value of E-cadherin expression in 413 gastric carcinomas. Int J Cancer 1996; 69: 184-9.
134. Mohri Y. Prognostic significance of E-cadherin expression in human colorectal cancer tissue. Surg Today 1997; 27: 606-12.
135. Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Choux R et al. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol 1998; 109: 431-8.
136. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN et al. Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997; 182: 331-8.
137. Franchi A, Gallo O, Boddi V, Santucci M. Prediction of occult neck metastases in laryngeal carcinoma: role of proliferating cell nuclear antigen, MIB-1, and E-cadherin immunohistochemical determination. Clin Cancer Res 1996; 2: 1801-8.
138. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava EM, Kosma VM. Reduced expression of alpha catenin is associated with poor prognosis in colorectal carcinoma. J Clin Pathol 1999; 52: 10-16.
139. Andrews NA, Jones AS, Helliwell TR, Kinsella AR. Expression of the E-cadherin-catenin cell adhesion complex in primary squamous cell carcinomas of the head and neck and their nodal metastases. Br J Cancer 1997; 75: 1474-80.
140. Ilyas M, Novelli M, Wilkinson K, Tomlinson IP, Abbasi AM, Forbes A et al. Tumour recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancers. J Clin Pathol 1997; 50: 218-22.
141. Jian WG, Darnton SJ, Jenner K, Billingham LJ, Matthews HR. Expression of E-cadherin in oesophageal carcinomas from the UK and China: disparities in prognostic significance. J Clin Pathol 1997; 50: 640-4.
142. Gunther K, Brabletz T, Kraus C, Dworak O, Reymond MA, Jung A et al. Predictive value of nuclear beta-catenin expression for the occurrence of distant metastases in rectal cancer. Dis Colon Rectum 1998; 41: 1256-61.
143. Gofuku J, Shiozaki H, Tsujinaka T, Inoue M, Tamura S, Doki Y et al. Expression of E-cadherin and alpha-catenin in patients with colorectal carcinoma. Correlation with cancer invasion and metastasis. Am J Clin Pathol 1999; 111: 29-37.
144. Gupta SK, Douglas-Jones AG, Jasani B, Morgan JM, Pignatelli M, Mansel RE. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast. Virchows Arch 1997; 430: 23-8.
145. Jawhari A, Jordan S, Poole S, Browne P, Pignatelli M, Farthing MJ. Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 1997; 112: 46-54.
146. Griffiths TR, Brotherick I, Bishop RI, White MD, McKenna DM, Horne CH et al. Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer 1996; 74: 579-84.
147. Durkan GC, Brotherick I, Mellon JK. The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin. Br J Urol 1999; 83: 424-8.
148. Gofuku J, Shiozaki H, Doki Y, Inoue M, Hirao M, Fukuchi N et al. Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. Br J Cancer 1998; 78: 1095-101.
149. Gadducci A, Ferdeghini M, Cosio S, Annicchiarico C, Ciampi B, Bianchi R et al. Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res 1999; 19: 769-72.
150. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76: 941-53.
151. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G et al. Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopathology 1999; 34: 25-34.
152. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD et al. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 1999; 5: 25-33.
153. Cowley GP, Smith ME. Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer 1995; 60: 325-9.
154. Gunji N, Oda T, Todoroki T, Kanazawa N, Kawamoto T, Yuzawa K et al. Pancreatic carcinoma: correlation between E-cadherin and alpha-catenin expression status and liver metastasis. Cancer 1998; 82: 1649-56.
155. Smith ME, Pignatelli M. The molecular histology of neoplasia: the role of the cadherin/catenin complex. Histopathology 1997; 31: 107-11.
156. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989; 80: 459-63.
157. Mareel MM, Behrens J, Birchmeier W, De Bruyne GK, Vleminckx K, Hoogewijs A et al. Down-regulation of E-cadherin expression in Madin Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J Cancer 1991; 47: 922-8.
158. Bracke ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo V. Tamoxifen restores the E-cadherin function in human breast cancer MCF-7/6 cells and suppresses their invasive phenotype. Cancer Res 1994; 54: 4607-9.
159. Vermeulen SJ, Bruyneel EA, van Roy FM, Mareel MM, Bracke ME. Activation of the E-cadherin/catenin complex in human MCF-7 breast cancer cells by all-trans-retinoic acid. Br J Cancer 1995; 72: 1447-53.
160. Fujimoto J, Ichigo S, Hori M, Morishita S, Tamaya T. Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and alpha- and beta-catenin mRNA expressions. J Steroid Biochem Mol Biol 1996; 57: 275-82.
161. Guvakova MA, Surmacz E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. Exp Cell Res 1997; 231: 149-62.
162. Matarrese P, Giandomenico V, Fiorucci G, Rivabene R, Straface E, Romeo G et al. Antiproliferative activity of interferon alpha and retinoic acid in SiHa carcinoma cells: the role of cell adhesion. Int J Cancer 1998; 76: 531-40.
163. Kester HA, van der Leede BM, van der Saag PT, van der Burg B. Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 1997; 272: 16 637-43.
164. Ryuto M, Jimi S, Ono M, Naito S, Nakayama Y, Yamada Y et al. All-trans-retinoic acid-dependent inhibition of E-cadherin-based cell adhesion with concomitant dephosphorylation of beta-catenin in metastatic human renal carcinoma cells. Jpn J Cancer Res 1997; 88: 982-91.
165. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225-31.